Udemy
    •  
    •  
    •  
    •  
    •  
    •  
    •  
    •  
Subscribe
Turn what you know into an opportunity and reach millions around the world.
Learn More
Your cart is empty.
Keep shopping
Cancer Signaling Pathways and Targeted Therapy
Rating: 4.8 out of 5(37 ratings)
622 students

Cancer Signaling Pathways and Targeted Therapy

Molecular Biology, Precision Medicine, Oncogenic Signaling, Cancer Resistance
Created byRadwan Derbala
Last updated 2/2025
English

What you'll learn

  • Understand the basics of Cell Signaling
  • Understand the MAPK Pathway and the Targeted therapies developed for it
  • Understand the PI3K Pathway and the Targeted therapies developed for it
  • Understand the Targeted Therapies related to the tumor microenvironment

Explore related topics

Course content

9 sections • 20 lectures • 2h 29m total length

  • Course Syllabus1:05

    Explore cancer signaling basics by examining receptors, the MAPK and PI3K pathways, and their targeted therapies, including resistance mechanisms. Learn about angiogenesis targets and how immunotherapy enhances T cell activity.

  • Disclaimer and References0:28

    Learn course disclaimers and how each mini lecture differs, access the resources icon and the downloadable tumorigenesis file, and see how literature is defined with attached references in this document.

Requirements

  • Basics of Cell Biology (transcription-translation-cell cycle-cell organelles)
  • Basics of Cancer Biology (Oncogene - Tumor Suppressor - Malignant/Benign - Stages of Tumor)

Description

The course provides the basics of cell signaling and how the cell division is controlled in the multicellular organisms. The course discusses each signaling pathway and the targeted therapies developed for it. Importantly, the course focuses on delivering the real-life examples from clinical trials so that the participant can have a robust idea on the benefits that the targeted therapies provide while being aware of the challenges that face the medical field. The participant at the end of the course has to know that there is no silver bullet for all cancers, not only that but also how the pharmaceutical industry shifted their focus from the histological segmentation of patients to the genomic one, which then rewarded them with better results and more drug approvals that tend to reach up to 40% from total fda approved drugs each year. Last but not least, the participant in that course will get familiar with several side effects of the inhibition of certain pathways, and how the same pathway can lead to different outcomes in different cell types.

The course will discuss only the MAPK, PI3K, Angiogenesis-HIF , Apoptosis-BCL2 (soon), and briefly the PDL1 signaling. In addition, the course will discuss several well known oncogenic mutations in the receptors and their targeted therapies.

Who this course is for:

  • Medical Students (from 3rd year) and Oncologists
  • Pharmacologists and Pharmacology students (from 3rd year)
  • Science and Biotechnology Students (from 3rd year) and Researchers
  • Bioinformaticians and Computational Biologists

Report abuse